<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5081">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01175590</url>
  </required_header>
  <id_info>
    <org_study_id>631</org_study_id>
    <nct_id>NCT01175590</nct_id>
  </id_info>
  <brief_title>Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle</brief_title>
  <official_title>A Study to Evaluate the Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle Following Three Times Daily(TID) Dosing for 7 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety of Besivance (besifloxacin ophthalmic
      suspension, 0.6%) compared to vehicle.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Ocular Treatment Emergent Adverse Events</measure>
    <time_frame>At each visit - 7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ocular Treatment-Emergent Adverse Events on the Study Eye</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-Ocular Treatment-Emergent Adverse Events</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Non-Ocular Treatment-Emergent Adverse Events on the Study Eye</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Resolution</measure>
    <time_frame>Day 8 (Visit 2)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The absence of both conjunctival discharge and bulbar conjunctival injection, after seven days of treatment. Participants with non-missing data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Resolution</measure>
    <time_frame>Day 11 (Visit 3)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The absence of both conjunctival discharge and bulbar conjunctival injection, after seven days of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbial Eradication</measure>
    <time_frame>Days 8 (Visit 2)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The absence of all accepted ocular bacterial species that were present at or above threshold at baseline, after seven days of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbial Eradication</measure>
    <time_frame>Days 11 (Visit 3)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The absence of all accepted ocular bacterial species that were present at or above threshold at baseline, after seven days of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbial Outcome With Clinical Resolution</measure>
    <time_frame>Day 8 (Visit 2)</time_frame>
    <safety_issue>No</safety_issue>
    <description>At each follow-up visit for the accepted ocular bacterial species that were present at or above threshold at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbial Outcome With Clinical Resolution</measure>
    <time_frame>Day 11 (Visit 3)</time_frame>
    <safety_issue>No</safety_issue>
    <description>At each follow-up visit for the accepted ocular bacterial species that were present at or above threshold at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Clinical Outcomes - Ocular Discharge</measure>
    <time_frame>At day 1 (Vist 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>ocular conjunctival discharge measured as absent, mild, moderate or severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Clinical Outcomes - Ocular Discharge</measure>
    <time_frame>At day 8 (Vist 2)</time_frame>
    <safety_issue>No</safety_issue>
    <description>ocular conjunctival discharge measured as absent, mild, moderate or severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Clinical Outcomes - Ocular Discharge</measure>
    <time_frame>At day 11 (Vist 3)</time_frame>
    <safety_issue>No</safety_issue>
    <description>ocular conjunctival discharge measured as absent, mild, moderate or severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Clinical Outcomes - Bulbar Injection</measure>
    <time_frame>At day 1 (Vist 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bulbar conjunctival injection measured as normal, mild, moderate or severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Clinical Outcomes - Bulbar Injection</measure>
    <time_frame>At day 8 (Vist 2)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bulbar conjunctival injection measured as normal, mild, moderate or severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Clinical Outcomes - Bulbar Injection</measure>
    <time_frame>At day 11 (Vist 3)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bulbar conjunctival injection measured as normal, mild, moderate or severe</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">518</enrollment>
  <condition>Bacterial Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Besivance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>besifloxacin ophthalmic suspension 0.6%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of Besivance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Besivance</intervention_name>
    <description>Ocular administration to affected eye for 7 days</description>
    <arm_group_label>Besivance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Vehicle of Besivance administered to affected eye for 7 days</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have a clinical diagnosis of acute bacterial conjunctivitis and exhibit
             purulent conjunctival discharge (crusty or sticky eyelids) and redness in at least
             one eye.

          -  Subjects who are willing to discontinue contact lens wear for the duration of the
             study.

          -  Subjects who are able and willing to comply with all treatment and follow- up/study
             procedures.

        Exclusion Criteria:

          -  Subjects who have any uncontrolled systemic disease or debilitating disease.

          -  Subjects with a known hypersensitivity or contraindications to Besivance,
             fluoroquinolones, or any of the ingredients in the study drugs.

          -  Subjects who are expected to require disallowed concurrent systemic or ocular
             therapy(either eye)during or prior to study start. (ie, NSAIDs, corticosteroids, mast
             cell stabilizers, antihistamines, decongestants or antimicrobial therapy)

          -  Subjects having ocular surgery (including laser surgery) in either eye within six
             weeks prior to entry into this study.

          -  Subjects with suspected viral or allergic conjunctivitis or any other disease
             conditions that could interfere with the efficacy and safety evaluations of the study
             medication.

          -  Subjects with suspected iritis.

          -  Subjects with a history of recurrent corneal erosion syndrome, either idiopathic or
             secondary to previous corneal trauma or dry eye syndrome.

          -  Subjects with any active ulcerative keratitis, specifically any epithelial loss
             greater than punctate keratitis.

          -  Subjects who are immune compromised.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Allaire, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 19, 2013</lastchanged_date>
  <firstreceived_date>August 3, 2010</firstreceived_date>
  <firstreceived_results_date>February 13, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Besifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First participant entered the study 6/22/2010 and the last participant visit was 12/12/2011. Twenty four sites in the United States participated in the study.</recruitment_details>
      <pre_assignment_details>518 participants with a clinical diagnosis of bacterial conjunctivitis were enrolled in the study, 496 completed the study; 518 participants were in Intent-to-Treat (ITT) population, 514 participants were in Safety population, and 299 participants were in modified Intent-to-Treat (mITT) population (Participants with positive culture at baseline).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Besivance</title>
          <description>besifloxacin ophthalmic suspension 0.6%
Besivance : Ocular administration to affected eye for 7 days</description>
        </group>
        <group group_id="P2">
          <title>Vehicle</title>
          <description>Vehicle of Besivance
Vehicle : Vehicle of Besivance administered to affected eye for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="347"/>
                <participants group_id="P2" count="171"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Intent to Treat Population</title>
              <participants_list>
                <participants group_id="P1" count="212"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="344"/>
                <participants group_id="P2" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="335"/>
                <participants group_id="P2" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Residual Bacterial Conjunctivitis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treated not as randomized</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Herpes Simplex Dermatitis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to treat population (ITT)</population>
      <group_list>
        <group group_id="B1">
          <title>Besivance</title>
          <description>besifloxacin ophthalmic suspension 0.6%
Besivance : Ocular administration to affected eye for 7 days</description>
        </group>
        <group group_id="B2">
          <title>Vehicle</title>
          <description>Vehicle of Besivance
Vehicle : Vehicle of Besivance administered to affected eye for 7 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="347"/>
                <measurement group_id="B2" value="171"/>
                <measurement group_id="B3" value="518"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>0-17 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="149"/>
                <measurement group_id="B2" value="62"/>
                <measurement group_id="B3" value="211"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>18 - 49 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="106"/>
                <measurement group_id="B2" value="71"/>
                <measurement group_id="B3" value="177"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=50 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="92"/>
                <measurement group_id="B2" value="38"/>
                <measurement group_id="B3" value="130"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="205"/>
                <measurement group_id="B2" value="95"/>
                <measurement group_id="B3" value="300"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="142"/>
                <measurement group_id="B2" value="76"/>
                <measurement group_id="B3" value="218"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="83"/>
                <measurement group_id="B2" value="40"/>
                <measurement group_id="B3" value="123"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="213"/>
                <measurement group_id="B2" value="103"/>
                <measurement group_id="B3" value="316"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="39"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="58"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ocular Treatment Emergent Adverse Events</title>
        <description>Ocular Treatment-Emergent Adverse Events on the Study Eye</description>
        <time_frame>At each visit - 7 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Besivance</title>
            <description>besifloxacin ophthalmic suspension 0.6% Besivance : Ocular administration to affected eye for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of Besivance
Vehicle : Vehicle of Besivance administered to affected eye for 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="344"/>
                  <measurement group_id="O2" value="170"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="344"/>
                  <measurement group_id="O2" value="170"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Ocular Treatment Emergent Adverse Events</title>
            <description>Ocular Treatment-Emergent Adverse Events on the Study Eye</description>
            <units>Events</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Conjunctivitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3" lower_limit="0.2" upper_limit="3"/>
                  <measurement group_id="O2" value="3" lower_limit="0.4" upper_limit="5.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blepharitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.0" upper_limit="1.6"/>
                  <measurement group_id="O2" value="1" lower_limit="0.0" upper_limit="3.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Conjunctival Oedema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.0" upper_limit="1.6"/>
                  <measurement group_id="O2" value="1" lower_limit="0.0" upper_limit="3.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Erythema of Eyelid</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2" lower_limit="0.1" upper_limit="2.1"/>
                  <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Punctate Keratitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.0" upper_limit="1.6"/>
                  <measurement group_id="O2" value="1" lower_limit="0.0" upper_limit="3.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Conjunctival Haemorrhage</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.0" upper_limit="1.6"/>
                  <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Conjunctivitis Allergic</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="0.0"/>
                  <measurement group_id="O2" value="1" lower_limit="0.0" upper_limit="3.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Corneal Infiltrates</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.0" upper_limit="1.6"/>
                  <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dacryocystitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.0" upper_limit="1.6"/>
                  <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Eye Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.0" upper_limit="1.6"/>
                  <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lacrimation Increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.0" upper_limit="1.6"/>
                  <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Scleritis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="0.0"/>
                  <measurement group_id="O2" value="1" lower_limit="0.0" upper_limit="3.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Instillation Site Reaction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2" lower_limit="0.1" upper_limit="2.1"/>
                  <measurement group_id="O2" value="1" lower_limit="0.0" upper_limit="3.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Instillation Site Erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.0" upper_limit="1.6"/>
                  <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Instillation Site Irritation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="0.0"/>
                  <measurement group_id="O2" value="1" lower_limit="0.0" upper_limit="3.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Instillation Site Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.0" upper_limit="1.6"/>
                  <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="0.0"/>
                  <measurement group_id="O2" value="1" lower_limit="0.0" upper_limit="3.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Herpes Dermatitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.0" upper_limit="1.6"/>
                  <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post-Traumatic Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="0.0"/>
                  <measurement group_id="O2" value="1" lower_limit="0.0" upper_limit="3.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Corneal Staining</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.0" upper_limit="1.6"/>
                  <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="0.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Resolution</title>
        <description>The absence of both conjunctival discharge and bulbar conjunctival injection, after seven days of treatment. Participants with non-missing data</description>
        <time_frame>Day 8 (Visit 2)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Study eye for the mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Besivance</title>
            <description>besifloxacin ophthalmic suspension 0.6%
Besivance : Ocular administration to affected eye for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of Besivance
Vehicle : Vehicle of Besivance administered to affected eye for 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="206"/>
                  <measurement group_id="O2" value="83"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="206"/>
                  <measurement group_id="O2" value="83"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Resolution</title>
            <description>The absence of both conjunctival discharge and bulbar conjunctival injection, after seven days of treatment. Participants with non-missing data</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="112"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Resolution</title>
        <description>The absence of both conjunctival discharge and bulbar conjunctival injection, after seven days of treatment.</description>
        <time_frame>Day 11 (Visit 3)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Study eye for the mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Besivance</title>
            <description>besifloxacin ophthalmic suspension 0.6%
Besivance : Ocular administration to affected eye for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of Besivance
Vehicle : Vehicle of Besivance administered to affected eye for 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="204"/>
                  <measurement group_id="O2" value="84"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Resolution</title>
            <description>The absence of both conjunctival discharge and bulbar conjunctival injection, after seven days of treatment.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="169"/>
                  <measurement group_id="O2" value="68"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbial Eradication</title>
        <description>The absence of all accepted ocular bacterial species that were present at or above threshold at baseline, after seven days of treatment.</description>
        <time_frame>Days 8 (Visit 2)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Study Eye, Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Besivance</title>
            <description>besifloxacin ophthalmic suspension 0.6%
Besivance : Ocular administration to affected eye for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of Besivance
Vehicle : Vehicle of Besivance administered to affected eye for 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="206"/>
                  <measurement group_id="O2" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="206"/>
                  <measurement group_id="O2" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Microbial Eradication</title>
            <description>The absence of all accepted ocular bacterial species that were present at or above threshold at baseline, after seven days of treatment.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="172"/>
                  <measurement group_id="O2" value="36"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbial Eradication</title>
        <description>The absence of all accepted ocular bacterial species that were present at or above threshold at baseline, after seven days of treatment.</description>
        <time_frame>Days 11 (Visit 3)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Study Eye, Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Besivance</title>
            <description>besifloxacin ophthalmic suspension 0.6%
Besivance : Ocular administration to affected eye for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of Besivance
Vehicle : Vehicle of Besivance administered to affected eye for 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="200"/>
                  <measurement group_id="O2" value="83"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="200"/>
                  <measurement group_id="O2" value="83"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Microbial Eradication</title>
            <description>The absence of all accepted ocular bacterial species that were present at or above threshold at baseline, after seven days of treatment.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="169"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Non-Ocular Treatment-Emergent Adverse Events</title>
        <description>Non-Ocular Treatment-Emergent Adverse Events on the Study Eye</description>
        <time_frame>7 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Besivance</title>
            <description>besifloxacin ophthalmic suspension 0.6%
Besivance : Ocular administration to affected eye for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of Besivance
Vehicle : Vehicle of Besivance administered to affected eye for 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="344"/>
                  <measurement group_id="O2" value="170"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Non-Ocular Treatment-Emergent Adverse Events</title>
            <description>Non-Ocular Treatment-Emergent Adverse Events on the Study Eye</description>
            <units>Events</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Ear Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.0" upper_limit="1.6"/>
                  <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dysgeusia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.0" upper_limit="1.6"/>
                  <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pyrexia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.0" upper_limit="1.6"/>
                  <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nasopharyngitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2" lower_limit="0.1" upper_limit="2.1"/>
                  <measurement group_id="O2" value="1" lower_limit="0.0" upper_limit="3.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bronchitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="0.0"/>
                  <measurement group_id="O2" value="1" lower_limit="0.0" upper_limit="3.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastroenteritis, Viral</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="0.0"/>
                  <measurement group_id="O2" value="1" lower_limit="0.0" upper_limit="3.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Otitis Media</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.0" upper_limit="1.6"/>
                  <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.0" upper_limit="1.6"/>
                  <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="0.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbial Outcome With Clinical Resolution</title>
        <description>At each follow-up visit for the accepted ocular bacterial species that were present at or above threshold at baseline</description>
        <time_frame>Day 8 (Visit 2)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Besivance</title>
            <description>besifloxacin ophthalmic suspension 0.6%
Besivance : Ocular administration to affected eye for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of Besivance
Vehicle : Vehicle of Besivance administered to affected eye for 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="206"/>
                  <measurement group_id="O2" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Microbial Outcome With Clinical Resolution</title>
            <description>At each follow-up visit for the accepted ocular bacterial species that were present at or above threshold at baseline</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Clinical Resolution with Microbial Eradication</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="96"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Clinical Resolution with no Microbial Eradication</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No Clinical Resolution with Microbial Eradication</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="76"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No Clinical Resolution no Microbial Eradication</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbial Outcome With Clinical Resolution</title>
        <description>At each follow-up visit for the accepted ocular bacterial species that were present at or above threshold at baseline</description>
        <time_frame>Day 11 (Visit 3)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Besivance</title>
            <description>besifloxacin ophthalmic suspension 0.6%
Besivance : Ocular administration to affected eye for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of Besivance
Vehicle : Vehicle of Besivance administered to affected eye for 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="200"/>
                  <measurement group_id="O2" value="83"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="200"/>
                  <measurement group_id="O2" value="83"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Microbial Outcome With Clinical Resolution</title>
            <description>At each follow-up visit for the accepted ocular bacterial species that were present at or above threshold at baseline</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Clinical Resolution with Microbial Eradication</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="143"/>
                  <measurement group_id="O2" value="42"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Clinical Resolution with no Microbial Eradication</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No Clinical Resolution with Microbial Eradication</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No Clinical Resolution no Microbial Eradication</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Clinical Outcomes - Ocular Discharge</title>
        <description>ocular conjunctival discharge measured as absent, mild, moderate or severe</description>
        <time_frame>At day 1 (Vist 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Baseline-Designated Study Eye (Modified Intent-to- Treat Population)</population>
        <group_list>
          <group group_id="O1">
            <title>Besivance</title>
            <description>besifloxacin ophthalmic suspension 0.6%
Besivance : Ocular administration to affected eye for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of Besivance
Vehicle : Vehicle of Besivance administered to affected eye for 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="212"/>
                  <measurement group_id="O2" value="87"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="212"/>
                  <measurement group_id="O2" value="87"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Individual Clinical Outcomes - Ocular Discharge</title>
            <description>ocular conjunctival discharge measured as absent, mild, moderate or severe</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Absent</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="94"/>
                  <measurement group_id="O2" value="38"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Clinical Outcomes - Ocular Discharge</title>
        <description>ocular conjunctival discharge measured as absent, mild, moderate or severe</description>
        <time_frame>At day 8 (Vist 2)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Baseline-Designated Study Eye (Modified Intent-to- Treat Population)</population>
        <group_list>
          <group group_id="O1">
            <title>Besivance</title>
            <description>besifloxacin ophthalmic suspension 0.6%
Besivance : Ocular administration to affected eye for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of Besivance
Vehicle : Vehicle of Besivance administered to affected eye for 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="206"/>
                  <measurement group_id="O2" value="83"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="206"/>
                  <measurement group_id="O2" value="83"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Individual Clinical Outcomes - Ocular Discharge</title>
            <description>ocular conjunctival discharge measured as absent, mild, moderate or severe</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Absent</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="155"/>
                  <measurement group_id="O2" value="61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Clinical Outcomes - Ocular Discharge</title>
        <description>ocular conjunctival discharge measured as absent, mild, moderate or severe</description>
        <time_frame>At day 11 (Vist 3)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Baseline-Designated Study Eye (Modified Intent-to- Treat Population)</population>
        <group_list>
          <group group_id="O1">
            <title>Besivance</title>
            <description>besifloxacin ophthalmic suspension 0.6%
Besivance : Ocular administration to affected eye for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of Besivance
Vehicle : Vehicle of Besivance administered to affected eye for 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="204"/>
                  <measurement group_id="O2" value="84"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="204"/>
                  <measurement group_id="O2" value="84"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Individual Clinical Outcomes - Ocular Discharge</title>
            <description>ocular conjunctival discharge measured as absent, mild, moderate or severe</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Absent</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="187"/>
                  <measurement group_id="O2" value="77"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Clinical Outcomes - Bulbar Injection</title>
        <description>Bulbar conjunctival injection measured as normal, mild, moderate or severe</description>
        <time_frame>At day 1 (Vist 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Baseline-Designated Study Eye (Modified Intent-to- Treat Population)</population>
        <group_list>
          <group group_id="O1">
            <title>Besivance</title>
            <description>besifloxacin ophthalmic suspension 0.6%
Besivance : Ocular administration to affected eye for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of Besivance
Vehicle : Vehicle of Besivance administered to affected eye for 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="212"/>
                  <measurement group_id="O2" value="87"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="212"/>
                  <measurement group_id="O2" value="87"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Individual Clinical Outcomes - Bulbar Injection</title>
            <description>Bulbar conjunctival injection measured as normal, mild, moderate or severe</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Normal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="110"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="83"/>
                  <measurement group_id="O2" value="37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Clinical Outcomes - Bulbar Injection</title>
        <description>Bulbar conjunctival injection measured as normal, mild, moderate or severe</description>
        <time_frame>At day 8 (Vist 2)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Baseline-Designated Study Eye (Modified Intent-to- Treat Population)</population>
        <group_list>
          <group group_id="O1">
            <title>Besivance</title>
            <description>besifloxacin ophthalmic suspension 0.6%
Besivance : Ocular administration to affected eye for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of Besivance
Vehicle : Vehicle of Besivance administered to affected eye for 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="206"/>
                  <measurement group_id="O2" value="83"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="206"/>
                  <measurement group_id="O2" value="83"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Individual Clinical Outcomes - Bulbar Injection</title>
            <description>Bulbar conjunctival injection measured as normal, mild, moderate or severe</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Normal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="142"/>
                  <measurement group_id="O2" value="57"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Clinical Outcomes - Bulbar Injection</title>
        <description>Bulbar conjunctival injection measured as normal, mild, moderate or severe</description>
        <time_frame>At day 11 (Vist 3)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Baseline-Designated Study Eye (Modified Intent-to- Treat Population)</population>
        <group_list>
          <group group_id="O1">
            <title>Besivance</title>
            <description>besifloxacin ophthalmic suspension 0.6%
Besivance : Ocular administration to affected eye for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of Besivance
Vehicle : Vehicle of Besivance administered to affected eye for 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="204"/>
                  <measurement group_id="O2" value="84"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="204"/>
                  <measurement group_id="O2" value="84"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Individual Clinical Outcomes - Bulbar Injection</title>
            <description>Bulbar conjunctival injection measured as normal, mild, moderate or severe</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Normal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="182"/>
                  <measurement group_id="O2" value="72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>11 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Besivance</title>
          <description>besifloxacin ophthalmic suspension 0.6%
Besivance : Ocular administration to affected eye for 7 days</description>
        </group>
        <group group_id="E2">
          <title>Vehicle</title>
          <description>Vehicle of Besivance
Vehicle : Vehicle of Besivance administered to affected eye for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed. Prior to publication or presentation, a copy of the final text should be forwarded by the Investigator(s) to the Sponsor or its designee, for comment.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tuyen Ong, MD, MRCOphth</name_or_title>
      <organization>Bausch &amp; Lomb Inc.</organization>
      <phone>(973) 360-6389</phone>
      <email>tuyen.ong@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
